Frequency of CD8+ T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers

Virology

Volumn 264, Issue 2, 1999, Pages 289-297

  Benninger Döring, Gerlinde ^a   Pepperl, Sandra ^b   Deml, Ludwig ^a   Modrow, Susanne ^a   Wolf, Hans ^a   Jilg, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A3 ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CALCULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; IMMEDIATE EARLY GENE; IMMUNE RESPONSE; INFECTIOUS MONONUCLEOSIS; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; VIRION; VIRUS CARRIER; VIRUS REPLICATION;

EID: 0345148395     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9996     Document Type: Article

References (49)

1. Biggin M., Bodescot M., Perricaudet M., Farell P. Epstein-Barr virus gene expression in P3HR-1-superinfected Raji cells. J. Virol. 61:1987;3120-3132.
2. Bogedain C., Alliger P., Schwarzmann F., Marschall M., Wolf H., Jilg W. Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J. Virol. 68:1994;1200-1203.
3. Bogedain C., Wolf H., Modrow S., Stuber G., Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J. Virol. 69:1995;4872-4879.
4. Burrows S. R., Khanna R., Burrows J. M., Moss D. J. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft-versus-host disease. J. Exp. Med. 179:1994;1155-1161.
5. + T cells during the primary immune response to Epstein-Barr virus In vivo. J. Exp. Med. 187:1998;1395-1402.
6. Elliott S. L., Pye S. J., Schmidt C., Cross S. M., Silins S. L., Misko I. S. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. J. Infect. Dis. 176:1997;1068-1072.
7. Gallimore A., Hengartner H., Zinkernagel R. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunol. Rev. 164:1998;29-36.
8. Haque T., Amlot P. L., Helling N., Thomas J. A., Sweny P., Rolles K., Burroughs A. K., Prentice H. G., Crawford D. H. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J. Immunol. 160:1998;6204-6209.
9. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J. Immunol. Methods. 203:1997;141-152.
10. + T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J. Infect. Dis. 178:1998;260-265.
11. Heslop H. E., Rooney C. M. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157:1997;217-222.
12. Heslop H. E., Ng C. Y., Li C., Smith C. A., Loftin S. K., Krance R. A., Brenner M. K., Rooney C. M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:1996;551-555.
13. Hickling, J. K. 1998, http://www-ermm.cbcu.cam.ak.uk ; Accession No. txt 001jhc.
14. Hill A. B., Lee S. P., Haurum J. S., Murray N., Yao Q. Y., Rowe M., Signoret N., Rickinson A. B., McMichael A. J. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J. Exp. Med. 181:1995;2221-2228.
15. Imanishi T., Akaza T., Kimura A., Tokunaga K., Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Tsuji K., Aizawa M., Sazazuki T. HLA 1991 Proceedings of the 11th International Histocompatibility Workshop and Conference. 1992;1065-1074 Oxford Univ. Press, London.
16. Jilg W., Bogedain C., Mairhofer H., Gu S. Y., Wolf H. The Epstein-Barr virus-encoded glycoprotein gp 110 (BALF 4) can serve as a target for antibody-dependent cell-mediated cytotoxicity (ADCC). Virology. 202:1994;974-977.
17. Khanna R., Burrows S. R., Moss D. J. Immune regulation in Epstein-Barr virus-associated diseases. Micobiol. Rev. 59:1995;387-405.
18. Khanna R., Burrows S. R., Neisig A., Neefjes J., Moss D. J., Silins S. L. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: Implications for epitope-based antiviral vaccines. J. Virol. 71:1997;7429-7435.
19. Kienzle N., Sculley T. B., Poulsen L., Buck M., Cross S., Raab-Traub N., Khanna R. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: A critical role for antigen expression. J. Virol. 72:1998;6614-6620.
20. Kuzushima K., Yamamoto M., Kimura H., Ando Y., Kudo T., Tsuge I., Morishima T. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin. Exp. Immunol. 103:1996;192-198.
21. + memory T cells. J. Exp. Med. 186:1997;859-865.
22. Lalvani A., Hill A. V. Cytotoxic T-lymphocytes against malaria and tuberculosis: From natural immunity to vaccine design. Clin. Sci. 95:1998;531-538.
23. Levitsky V., de Campos-Lima P. O., Frisan T., Masucci M. G. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161:1998;594-601.
24. Lohr H. F., Krug S., Herr W., Weyer S., Schlaak J., Wolfel T., Gerken G., Meyer Z. B. K. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver. 18:1998;405-413.
25. Masucci M. G., Ernberg I. Epstein-Barr virus: Adaptation to a life within the immune system. Trends Microbiol. 2:1994;125-130.
26. Modrow S., Höflacher B., Mellert K. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. J. Acquired Immune Defic. Syndr. 2:1989;21-27.
27. Pepperl S., Benninger-Doring G., Modrow S., Wolf H., Jilg W. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J. Virol. 72:1998;8644-8649.
28. Ragoczy T., Heston L., Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:1998;7978-7984.
29. Rammensee H. G., Friede T., Stevanoviic S. MHC ligands and peptide motifs: First listing. Immunogenetics. 41:1995;178-228.
30. Redchenko I. V., Rickinson A. B. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J. Virol. 73:1999;334-342.
31. Rickinson A. B., Moss D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:1997;405-431.
32. Rooney C. M., Heslop H. E., Brenner M. K. EBV specific CTL: A model for immune therapy. Vox Sang. 74:1998a;497-498.
33. Rooney C. M., Roskrow M. A., Smith C. A., Brenner M. K., Heslop H. E. Immunotherapy for Epstein-Barr virus-associated cancers. J. Natl. Cancer Inst. Monogr. 1998b;89-93.
34. Roskrow M. A., Suzuki N., Gan Y., Sixbey J. W., Ng C. Y., Kimbrough S., Hudson M., Brenner M. K., Heslop H. E., Rooney C. M. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 91:1998;2925-2934.
35. Rowe M., Lear A. L., Croom-Carter D., Davies A. H., Rickinson A. B. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:1992;122-131.
36. Rowland-Jones S. L., Dong T., Fowke K. R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., Bwayo J., MacDonald K. S., McMichael A. J., Plummer F. A. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1998;1758-1765.
37. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:1997a;221-226.
38. Scheibenbogen C., Lee K. H., Stevanovic S., Witzens M., Willhauck M., Waldmann V., Naeher H., Rammensee H. G., Keilholz U. Analysis of the T cell response to tumor and viral peptide antigens by an IFN-γ-ELISPOT assay. Int. J. Cancer. 71:1997b;932-936.
39. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods. 210:1997;167-174.
40. + cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol. 9:1997;1745-1755.
41. Steven N. M., Leese A. M., Annels N. E., Lee S. P., Rickinson A. B. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184:1996;1801-1813.
42. Steven N. M., Annels N. E., Kumar A., Leese A. M., Kurilla M. G., Rickinson A. B. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1997;1605-1617.
43. Suhrbier A. Multi-epitope DNA vaccines. Immunol. Cell Biol. 75:1997;402-408.
44. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 344:1990;818-819.
45. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1999;1827-1835.
46. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1981;1614-1619.
47. Thorley-Lawson D. A., Miyashita E. M., Khan G. Epstein-Barr virus and the B cell: That's all it takes. Trends Microbiol. 4:1996;204-208.
48. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology. 219:1996;489-492.
49. Zalani S., Holley-Guthrie E., Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell specific mechanism. Proc. Natl. Acad. Sci. USA. 93:1996;9194-9199.